{
    "clinical_study": {
        "@rank": "129256", 
        "acronym": "ASAP", 
        "arm_group": [
            {
                "arm_group_label": "Dietary Supplement: Anatabloc(R)", 
                "arm_group_type": "Active Comparator", 
                "description": "Study product, as mint-flavored lozenge (3 mg anatabine per lozenge) to be taken 2-3 times each day"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo, as mint-flavored lozenge, to be taken 2-3 times each day"
            }
        ], 
        "brief_summary": {
            "textblock": "To explore whether dietary supplementation with a version of Anatabloc(R) exerts an effect\n      on blood levels of amyloid beta (A\u03b2), or impacts global or functional measures of\n      Alzheimer's Disease (AD) in subjects with mild to moderate AD."
        }, 
        "brief_title": "Study to Evaluate Dietary Supplementation With a Version of Anatabloc(R) in Subjects With Alzheimer's Disease", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Alzheimer Disease", 
        "condition_browse": {
            "mesh_term": "Alzheimer Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  At least 65 years old.\n\n          -  Have a diagnosis of probable AD or a concurrent diagnosis of probable AD and possible\n             or probable vascular dementia.\n\n          -  Score 16 or more on the Mini-Mental State Examination (MMSE).\n\n          -  Otherwise stable medical history and general health.\n\n          -  Weigh between 45 kg and 120 kg inclusive.\n\n        Exclusion Criteria:\n\n          -  Have contra-indications, allergy, or sensitivity to the study products or their\n             components.\n\n          -  Be currently taking any of the following medications: systemic (oral or injectable)\n             glucocorticoids; interferon-alpha; anti-CD20 antibody (e.g., rituximab); or\n             anti-CTLA-4 antibody (e.g., ipilimumab).\n\n          -  Be a current smoker or smokeless tobacco user."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01669876", 
            "org_study_id": "RCP-009"
        }, 
        "intervention": [
            {
                "arm_group_label": "Dietary Supplement: Anatabloc(R)", 
                "description": "Dietary supplement Anatabloc(R), as a mint-flavored lozenge, to be taken 2-3 times each day", 
                "intervention_name": "Anatabloc(R)", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo, as a mint-flavored lozenge, to be taken 2-3  times each day", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Randomized", 
            "Double-Blind", 
            "Dietary Supplements"
        ], 
        "lastchanged_date": "March 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Sarasota", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "34243"
                }, 
                "name": "Roskamp Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "3-Month, Single Site or Multi-Site, Double Blind, Randomized, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety Tolerability and Potential Effects of the Dietary Supplement Anatabloc(R) in Subjects With Alzheimer's Disease", 
        "overall_official": {
            "affiliation": "Roskamp Institute", 
            "last_name": "A Keegan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Suspended", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Collected data on the numbers and types of adverse effects among subject  individuals with mild to moderate Alzheimer's disease (AD).", 
            "measure": "Number of subjects experiencing adverse effects when using the supplement", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01669876"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Changes in blood levels of amyloid beta (A\u03b2)", 
                "measure": "Measured changes in blood markers of AD", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Changes in subject's scores in global and functional measures of AD during the course of the study", 
                "measure": "Changes in global or functional measures of AD in subjects during the course of the study", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }
        ], 
        "source": "Rock Creek Pharmaceuticals, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Roskamp Institute Inc.", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Rock Creek Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014", 
        "why_stopped": "Pending clarification of the administrative status of active ingredient anatabine"
    }
}